Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

DXCM vs EW: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DXCM Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 6–4 Matrix Metrics)

DXCM Overall Winner 6-Pillar Tally: DXCM 3 – 3 EW Matrix Metrics: DXCM 6 – 4 EW

As of Nov 20, 2026, DexCom, Inc. (DXCM) is the stronger overall head-to-head candidate over Edwards Lifesciences Corp (EW) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, Options & Positioning). DXCM carries a Unified Composite Score of 50.8/100 (HOLD) at $79.32 (25.3x Forward P/E, 24.0% operating margin), whereas EW carries 40.0/100 (SELL) at $101.85 (30.1x Forward P/E, 28.8% operating margin).

  • Technical & Structure Timing Caution: DXCM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.0); meanwhile EW trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 59.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DXCM vs EW
DXCM NASDAQ Head-to-Head Winner
DexCom, Inc.
Surgical & Medical Instruments & Apparatus
$79.32
-1.08% 1D
Market Cap $29.9B
TTM Revenue $5.10B
Forward P/E 25.3x
Beta / 30D Vol 0.59β · 43% Vol
Unified Composite Score
50.8 / 100 HOLD
Tech 49.0 Fund 56.0 Flow 68.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.3%), weak momentum, RSI 43
RSI-14: 43.0 · SMA20: $81.49 · SMA50: $83.94
EW NYSE
Edwards Lifesciences Corp
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$101.85
-1.95% 1D
Market Cap $59.7B
TTM Revenue $6.67B
Forward P/E 30.1x
Beta / 30D Vol 0.43β · 27% Vol
Unified Composite Score
40.0 / 100 SELL
Tech 24.0 Fund 43.0 Flow 55.0 Mom 60.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (4.7% over 20 days), RSI 59
RSI-14: 59.1 · SMA20: $100.07 · SMA50: $92.22

6-Pillar Scorecard Institutional Category Breakdown (DXCM 3 – 3 EW)

Columns: Metric · DXCM · EW
1. Valuation Multiples DXCM
Forward P/E 25.3x 30.1x
Trailing P/E 31.6x 60.4x
PEG Ratio 1.30x 2.32x
EV / Revenue 5.9x 8.6x
2. Growth & Scale EW
Revenue Growth (YoY) +11.2% +10.5%
Earnings Growth (YoY) +2.6% +6.7%
TTM Revenue (USD) $5.10B $6.67B
Market Cap $29.9B $59.7B
3. Profitability & Quality EW
Gross Margin 63.4% 78.0%
Operating Margin 24.0% 28.8%
Net Profit Margin 19.4% 15.3%
Return on Equity (ROE) 37.7% 9.3%
4. Balance Sheet & Cash Flow DXCM
Cash Generation (TTM) $1.73B $1.42B
Cash Flow Margin 33.9% 21.3%
Net Cash / Leverage $432M Net Debt (0.55x D/E) $2.41B Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DXCM
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 63.0% (15th %ile) 173.0% (100th %ile)
Put/Call OI Skew 0.48x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat EW
OpEx & R&D Intensity 39.4% of Rev ($2.01B) 49.2% of Rev ($3.28B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Scale & Operating Efficiency Moat
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DXCM (6) vs EW (4)
Institutional Metric DXCM EW Criterion Row Edge
Market Capitalization
Scale
$29.9B $59.7B Larger Scale EW
Trailing P/E Ratio
Valuation
31.6x 60.4x Lower Multiple DXCM
Forward P/E Ratio
Valuation
25.3x 30.1x Lower Multiple DXCM
Revenue Growth (YoY)
Growth
+11.2% +10.5% Higher Growth DXCM
Operating Margin (TTM)
Profitability
24.0% 28.8% Higher Margin EW
Net Profit Margin
Profitability
19.4% 15.3% Higher Margin DXCM
Return on Equity (ROE)
Capital Efficiency
37.7% 9.3% Higher ROE DXCM
52-Week Range Position
Momentum
63% ($57–$93) 82% ($75–$108) Stronger Trend EW
Beta / 30D Volatility
Risk Regime
0.59β · 43% Vol 0.43β · 27% Vol Lower Realized Risk EW
Unified Institutional Score
Composite Signal
50.8 / 100 (HOLD) 40.0 / 100 (SELL) Higher Composite DXCM
Trailing 12M Revenue (USD)
Operating Scale
$5.10B $6.67B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
63.4% 78.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.30x PEG · 5.9x EV/Rev 2.32x PEG · 8.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$1.73B ($432M Net Debt (0.55x D/E)) $1.42B ($2.41B Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EW +11.77 pp
DXCM: +1.28% · EW: +13.05%
3M Horizon EW +25.43 pp
DXCM: -12.89% · EW: +12.54%
6M Horizon EW +8.72 pp
DXCM: +10.01% · EW: +18.73%
1Y Horizon DXCM +14.4 pp
DXCM: +32.8% · EW: +18.4%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period DXCM Revenue EW Revenue DXCM Op. Margin EW Op. Margin Margin Leader
FY2018 $1.03B $3.72B -18.1% 20.1% EW
FY2019 $1.48B $4.35B 9.6% 26.4% EW
FY2020 $1.93B $4.39B 15.5% 20.5% EW
FY2021 $2.45B $5.23B 10.9% 32.3% EW
FY2022 $2.91B $4.46B 13.4% 33.6% EW
FY2023 $3.62B $5.01B 16.5% 26.1% EW
FY2024 $4.03B $5.44B 14.9% 25.3% EW
FY2025 $4.66B $6.07B 19.6% 20.8% EW

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DXCM CONSOLIDATION
73d in phase · OBV ACCUMULATION
Current IV 63.0%
IV Percentile 15th %ile
Put/Call OI Skew 0.48x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact DXCM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
EW UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 173.0%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact EW Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $81.61 · IV 39.6%

DXCM vs. EW: Simulated 5-Day Option Payoffs & Capital Efficiency

Compare 100 shares of DXCM ($8,161) vs. EW ($10,543) against risk-defined 5-day vertical and put-wall option structures.

DXCM Spot $81.61 · IV 39.6%
DXCM Options Simulator →
5-DAY BULLISH SWING Liq B

Dec 18 $80 / $90 Bull Call Spread

Buy 1x $80C · Sell 1x $90C · 31d

Net Entry $482 Debit
T+5d @ +5% Move +$136 (+28%)
Max Risk / Buffer $482 Capped
5d Edge & Liquidity 0.7x R:R · Liq B
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq B

Dec 18 $75 / $70 Bull Put Spread

Sell 1x $75P · Buy 1x $70P · 31d

Net Entry $86 Credit
Max Credit / Yield +$86 (+20.8% RoM)
Max Risk / Buffer -9.2% Cushion ($414 Mgn)
5d Edge & Liquidity 78% PoP · Liq B
Simulate 5-Day Payoff →
EW Spot $105.43 · IV 28.2%
EW Options Simulator →
5-DAY BULLISH SWING Liq B

Dec 18 $105 / $110 Bull Call Spread

Buy 1x $105C · Sell 1x $110C · 30d

Net Entry $185 Debit
T+5d @ +5% Move +$124 (+67%)
Max Risk / Buffer $185 Capped
5d Edge & Liquidity 1.0x R:R · Liq B
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq B

Dec 18 $100 / $95 Bull Put Spread

Sell 1x $100P · Buy 1x $95P · 30d

Net Entry $64 Credit
Max Credit / Yield +$64 (+14.7% RoM)
Max Risk / Buffer -5.8% Cushion ($436 Mgn)
5d Edge & Liquidity 77% PoP · Liq B
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DXCM Moat Profile High-Margin Pricing Power Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $29.9B market capitalization and 24.0% operating margin.
OpEx & R&D Reinvestment 39.4% of Rev ($2.01B)
90D Engineering Disclosures 0 Published
EW Moat Profile Scale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $59.7B market capitalization and 28.8% operating margin.
OpEx & R&D Reinvestment 49.2% of Rev ($3.28B)
90D Engineering Disclosures 0 Published

Investor FAQ DXCM vs EW Key Questions & Quantitative Answers

As of Nov 20, 2026, DexCom, Inc. (DXCM) is the stronger overall head-to-head candidate over Edwards Lifesciences Corp (EW) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, Options & Positioning). DXCM carries a Unified Composite Score of 50.8/100 (HOLD) at $79.32 (25.3x Forward P/E, 24.0% operating margin), whereas EW carries 40.0/100 (SELL) at $101.85 (30.1x Forward P/E, 28.8% operating margin). Technical & Structure Timing Caution: DXCM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.0); meanwhile EW trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 59.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

EW leads the Growth & Scale pillar: DXCM posts +11.2% YoY revenue growth and +2.6% YoY earnings growth on $5.10B TTM revenue (63.4% gross margin, 24.0% operating margin), compared with EW at +10.5% YoY revenue growth and +6.7% YoY earnings growth on $6.67B TTM revenue (78.0% gross margin, 28.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), DXCM cumulative revenue shifted +352.4% while EW shifted +63.2%. In operating R&D and SG&A reinvestment, DXCM deploys 39.4% of Rev ($2.01B) (0 90-day corporate R&D disclosures) versus 49.2% of Rev ($3.28B) (0 disclosures) for EW.

DXCM screens cheaper on headline valuation multiples. DXCM trades at 25.3x Forward P/E, 31.6x Trailing P/E, 1.30x PEG, and 5.9x EV/Revenue (33.9% FCF margin), whereas EW trades at 30.1x Forward P/E, 60.4x Trailing P/E, 2.32x PEG, and 8.6x EV/Revenue (21.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DXCM (37.7% ROE) versus EW (9.3% ROE) capital efficiency.

In options market volatility and institutional positioning, DXCM carries 63.0% implied volatility (15th %ile, Compressed (<25th %ile)), a 0.48x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.59β · 43% Vol realized risk). By comparison, EW carries 173.0% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.43β · 27% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.